Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Latest Information Update: 29 Mar 2023
Price :
$35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms REGISTRI
- 18 Dec 2019 Planned End Date changed from 1 Nov 2020 to 1 Dec 2024.
- 18 Dec 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2023.
- 08 Jan 2016 New trial record